1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63F2075C9DE40229765257F8D0038A517
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/3F2075C9DE40229765257F8D0038A517!OpenDocument
18
19OpenDocument
2044.201.72.250
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Quality, Compliance and Regulatory » Deployment

Document Excerpt: REMS Excellence: Models & Trends in Supporting REMS Program Success

DB Image

ID: MD-511


Features:

13 Info Graphics

15 Data Graphics

180+ Metrics


Pages/Slides: 4


Published: Pre-2018


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

To download this excerpt, click
"Download Free Excerpt".


To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5410 "REMS Excellence: Models & Trends in Supporting REMS Program Success."


Industries Profiled:
Pharmaceutical; Health Care; Biotech; Biopharmaceutical; Clinical Research; Laboratories; Consulting; Manufacturing; Consumer Products; Diagnostic; Medical Device


Companies Profiled:
Abbvie; Sanofi; Novartis; Scientific Advantage; Arthur F. Morelli and Associates; UCB Pharma; Oxon Epidemiology; Baxter BioScience; Pfizer; Bayer; Reliance Life Sciences; Cadila Pharmaceuticals; Eisai; Gilead Sciences; Hospira; Lilly; MedicinesOracle

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.